Vol.59 No.S-1 May 2011

Phase I study of intravenous levofloxacin in healthy adult male volunteers

Kohya Shiba and Hiroyuki Fukase

Jpn. J. Chemother. 59 (S-1): 1-9, 2011

Evaluation of regimens reducing injection site reaction by intravenous levofloxacin in healthy subjects

Kohya Shiba, Shinichi Minamitani, Tomoyuki Monma and Hiroyuki Fukase

Jpn. J. Chemother. 59 (S-1): 10-17, 2011

Multicenter open-label phase II/III study of intravenous levofloxacin in subjects with respiratory tract infection

Shigeru Kohno, Akira Watanabe, Nobuki Aoki, Yoshihito Niki, Junichi Kadota, Jiro Fujita, Katsunori Yanagihara, Mitsuo Kaku and Seiji Hori

Jpn. J. Chemother. 59 (S-1): 18-31, 2011

Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment

Shigeru Kohno, Akira Watanabe, Nobuki Aoki, Yoshihito Niki, Junichi Kadota, Jiro Fujita, Katsunori Yanagihara, Mitsuo Kaku and Seiji Hori

Jpn. J. Chemother. 59 (S-1): 32-45, 2011

Safety profile of intravenous levofloxacin (500 mg once a day)

Seiji Hori and Shigeru Kohno

Jpn. J. Chemother. 59 (S-1): 46-54, 2011

Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection

Yusuke Tanigawara, Takako Shimizu and Kyoichi Totsuka

Jpn. J. Chemother. 59 (S-1): 55-64, 2011